These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16218775)

  • 1. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.
    Vilalta A; Mahajan RK; Hartikka J; Rusalov D; Martin T; Bozoukova V; Leamy V; Hall K; Lalor P; Rolland A; Kaslow DC
    Hum Gene Ther; 2005 Oct; 16(10):1143-50. PubMed ID: 16218775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.
    Vilalta A; Mahajan RK; Hartikka J; Leamy V; Martin T; Rusalov D; Bozoukova V; Lalor P; Hall K; Kaslow DC; Rolland A
    Hum Gene Ther; 2005 Oct; 16(10):1151-6. PubMed ID: 16218776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines.
    Leamy VL; Martin T; Mahajan R; Vilalta A; Rusalov D; Hartikka J; Bozoukova V; Hall KD; Morrow J; Rolland AP; Kaslow DC; Lalor PA
    Hum Vaccin; 2006; 2(3):113-8. PubMed ID: 17012905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection.
    Schleiss MR
    Curr Opin Mol Ther; 2009 Oct; 11(5):572-8. PubMed ID: 19806506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
    Selinsky C; Luke C; Wloch M; Geall A; Hermanson G; Kaslow D; Evans T
    Hum Vaccin; 2005; 1(1):16-23. PubMed ID: 17038834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.
    Vilalta A; Shlapobersky M; Wei Q; Planchon R; Rolland A; Sullivan S
    Vaccine; 2009 Dec; 27(52):7409-17. PubMed ID: 19735757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
    Hartikka J; Bozoukova V; Morrow J; Rusalov D; Shlapobersky M; Wei Q; Boutsaboualoy S; Ye M; Wloch MK; Doukas J; Sullivan S; Rolland A; Smith LR
    Hum Vaccin Immunother; 2012 Nov; 8(11):1595-606. PubMed ID: 22922766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.
    Doukas J; Morrow J; Bellinger D; Hilgert T; Martin T; Jones D; Mahajan R; Rusalov D; Sullivan S; Rolland A
    Vaccine; 2011 Jul; 29(33):5443-52. PubMed ID: 21641955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
    Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
    Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice.
    Huang C; Wang H; Wu S; Chang H; Liu L; Peng B; Fang F; Chen Z
    Virol J; 2014 Jun; 11():104. PubMed ID: 24898886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits.
    Parker SE; Borellini F; Wenk ML; Hobart P; Hoffman SL; Hedstrom R; Le T; Norman JA
    Hum Gene Ther; 1999 Mar; 10(5):741-58. PubMed ID: 10210142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine.
    Schleiss MR; Stroup G; Pogorzelski K; McGregor A
    Vaccine; 2006 Sep; 24(37-39):6175-86. PubMed ID: 16879902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.
    Abel K; Martinez J; Yue Y; Lacey SF; Wang Z; Strelow L; Dasgupta A; Li Z; Schmidt KA; Oxford KL; Assaf B; Longmate JA; Diamond DJ; Barry PA
    J Virol; 2011 Mar; 85(6):2878-90. PubMed ID: 21191005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations.
    Hartikka J; Geall A; Bozoukova V; Kurniadi D; Rusalov D; Enas J; Yi JH; Nanci A; Rolland A
    J Gene Med; 2008 Jul; 10(7):770-82. PubMed ID: 18425981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models.
    Quezada A; Larson J; French M; Ponce R; Perrard J; Durland R; Coleman M
    J Pharm Pharmacol; 2004 Feb; 56(2):177-85. PubMed ID: 15005876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
    Jacobson MA; Adler SP; Sinclair E; Black D; Smith A; Chu A; Moss RB; Wloch MK
    Vaccine; 2009 Mar; 27(10):1540-8. PubMed ID: 19168107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
    Reap EA; Morris J; Dryga SA; Maughan M; Talarico T; Esch RE; Negri S; Burnett B; Graham A; Olmsted RA; Chulay JD
    Vaccine; 2007 Oct; 25(42):7441-9. PubMed ID: 17870214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.
    Fu TM; Wang D; Freed DC; Tang A; Li F; He X; Cole S; Dubey S; Finnefrock AC; ter Meulen J; Shiver JW; Casimiro DR
    Vaccine; 2012 Dec; 30(52):7469-74. PubMed ID: 23107592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.